Nov 30, 2020
|
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
|
|
Nov 09, 2020
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Nov 04, 2020
|
MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results
|
|
Nov 04, 2020
|
MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020
|
|
Oct 28, 2020
|
MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call
|
|
Oct 15, 2020
|
MacroGenics Announces Flotetuzumab Publication in Blood Advances
|
|
Sep 23, 2020
|
MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics
|
|
Sep 22, 2020
|
MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood
|
|
Sep 21, 2020
|
MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte
|
|
Sep 20, 2020
|
MacroGenics Announces Presentation of MGD019 Phase 1 Data at the ESMO Virtual Congress 2020
|
|
Sep 03, 2020
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Aug 05, 2020
|
MacroGenics to Participate in Upcoming Investor Conferences
|
|
Jul 30, 2020
|
MacroGenics Provides Update on Corporate Progress and Second Quarter 2020 Financial Results
|
|
Jul 23, 2020
|
MacroGenics Announces Date of Second Quarter 2020 Financial Results Conference Call
|
|
Jul 09, 2020
|
MacroGenics Announces Lancet Oncology Publication of Margetuximab Data in Gastric Cancer
|
|
Jun 22, 2020
|
MacroGenics Announces Presentation of Preclinical Data at the 2020 AACR Annual Meeting
|
|
Jun 16, 2020
|
MacroGenics Appoints Dr. Stephen Eck As Chief Medical Officer
|
|
Jun 05, 2020
|
MacroGenics Announces Margetuximab Granted Orphan Drug Designation in the U.S. for Gastric Cancer
|
|
Jun 03, 2020
|
MacroGenics Announces Publication in Science Translational Medicine Supporting Flotetuzumab Pivotal Study in Patients with Refractory Acute Myeloid Leukemia
|
|
May 28, 2020
|
MacroGenics Provides Update on FDA Review of Margetuximab for HER2-Positive Metastatic Breast Cancer
|
|
May 27, 2020
|
MacroGenics Announces Registration Study of Flotetuzumab in Patients with Refractory Acute Myeloid Leukemia
|
|
May 21, 2020
|
MacroGenics to Host Conference Call and Webcast to Review Preliminary Clinical Results for MGD013 and MGC018 to be Presented at ASCO
|
|
May 13, 2020
|
MacroGenics Announces Preliminary Clinical Results from MGD013 and MGC018 to be Presented at the ASCO Annual Meeting
|
|
May 05, 2020
|
MacroGenics Provides Update on Corporate Progress and First Quarter 2020 Financial Results
|
|
Apr 29, 2020
|
MacroGenics Announces Presentations at the 2020 ASCO Annual Meeting
|
|